The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CoRInTH: A phase Ib/II trial of checkpoint inhibitor, pembrolizumab (PD-1 antibody [Ab]) plus standard intensity modulated chemoradiotherapy (IMCRT) in HPV-induced stage III squamous cell carcinoma (SCC) of the anus.
 
Marcia Hall
Honoraria - Clovis Oncology; GlaxoSmithKline
Consulting or Advisory Role - Clovis Oncology; GlaxoSmithKline
Research Funding - BMS (Inst); Clovis Oncology (Inst); Merck (Inst)
 
Richard Adams
Honoraria - Amgen; Merck Serono; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; SERVIER
Speakers' Bureau - Merck Serono
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck Serono; SERVIER
 
Marianne Grønlie Guren
No Relationships to Disclose
 
Margherita Carucci
No Relationships to Disclose
 
Lisette Nixon
No Relationships to Disclose
 
Catharine Porter
No Relationships to Disclose
 
Neel Bhuva
No Relationships to Disclose
 
Robert Glynne-Jones
No Relationships to Disclose
 
Mark Harrison
No Relationships to Disclose